Patent US4870071A successfully refreshed from Google Patents.
US4870071A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prophylactic and therapeutic agnet for hepatic disorder
Assignee: Senju Pharmaceutical Co Ltd
•
Filing: 1987-04-30
•
Granted: 1989-09-26
•
Expires: 2007-04-30
Abstract
Abstract There is provided the use of cysteineglucuronic acid, cysteineglucuronolactone and their salts as a prophylactic and therapeutic agent for hepatic disorder. By administering the compund to a subject in an oral dail does of 1 to 5,000 mg or parenteral daily dose of 1, to 2,000 mg, the elevation of GOT, GPT, LDH, ALP TG or HyP level is suppressed and hepatic disorders can be prevented or cured.
Inventors
- 👤 Kazumi Ogata
- 👤 Takahiro Sakaue
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 05:15
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/425; A61P; A61P1/00; A61P1/16
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
78 words
A process for suppressing the elevation of GOT, GPT, LDH or ALP level in blood, or TG or HyP level in liver, of a subject suffering from hepatic disorders, which comprises administering orally or parenterally to said subject an effective daily dose for suppressing said elevation of a pharmaceutical composition comprised of a therapeutically effective amount of a compound selected from the group consisting of cysteineglucuronic acid, cysteineglucuronolactone and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
78 words
A process for suppressing the elevation of GOT, GPT, LDH or ALP level in blood, or TG or HyP level in liver, of a subject suffering from hepatic disorders, which comprises administering orally or parenterally to said subject an effective daily dose for suppressing said elevation of a pharmaceutical composition comprised of a therapeutically effective amount of a compound selected from the group consisting of cysteineglucuronic acid, cysteineglucuronolactone and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
28 words
The process as claimed in claim 1, wherein the effective daily dose is 1 to 5000 mg for oral administration and 1 to 2000 mg for parenteral administration.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-09-25 | 1993-03-27 | 1993-09-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-09-25 | 1997-03-27 | 1997-09-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-09-25 | 2001-03-27 | 2001-09-26 | $7700.00 | Window Closed / Lapsed |